As a child, our founder sat in a hospital ward beside a boy his own age with acute myeloid leukemia. It was Myanmar; the diagnosis was slow, and care was scarce. The boy never made it home.
That memory is the reason Axiisium exists. AML moves fast; too often, the diagnosis cannot keep up. We are building the tool we wish that boy had had: one that turns a bone-marrow image into a clear, verifiable answer in time to matter, and that can one day reach the kinds of places where the answer arrives too late.
Most cell classifiers hand a clinician a guess. Axiisium hands them a diagnosis they can check. It reads the morphology, brings together the signals a diagnosis depends on, applies today's WHO and ICC criteria, and defers the hard calls to confirmatory testing, never inferring what it cannot know.
And every decision is signed to a tamper-evident record that anyone can verify, without trusting us. That accountability is what clinical AI needs to be trusted with a life.
A diagnosis that can begin from a smear image alone, the one input almost any hospital can produce.
Each call is bound to a public, tamper-evident record. Change one byte and verification fails.
We are committed to bringing Axiisium to low-resource settings, beginning with Myanmar, through grant-funded and non-profit partners, at no cost to the patients who need it. We are building the commercial foundation first, so that reaching those who cannot pay is something we can sustain, not just promise.
If you work in global health, pediatric oncology, or diagnostics access and this mission is yours too, we would like to hear from you.
Axiisium is early and in active development, a research-use tool today. We hold every claim to the same standard we hold the disease to, and we publish our results on real data as they stand, not before.
For the ones we remember, and the ones we can still reach.